SEVER LIFE SCIENCES B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), TO SHARE PATIENT DATA AND PATIENT EXPERIENCE STUDY FOR LACRIFILL® CANALICULAR GEL, A NOVEL THERAPY FOR OCULAR SURFACE CONTROL, DURING AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO) 2026
DOYLESTOWN, Pa., Oct. 7, 2026 /PRNewswire/ -- Nordic Pharma, Inc., a subsidiary of SEVER Life Sciences B.V., will feature LACRIFILL® Canalicular Gel, a novel therapy for ocular surface control, during the American Academy of Ophthalmology Annual Meeting in New Orleans, LA, from October...
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Résiliable à tout moment · 99 $ CA/mois


